Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals

Key Takeaways Pharvaris surged after RAPIDe-3 showed deucrictibant delivering far faster HAE symptom relief than placebo.The study met all primary and secondary endpoints, with most attacks treated by a single deucrictibant dose.PHVS plans to file for approval in 2026, as investors compare results with KALV's recently approved Ekterly.Shares of Pharvaris (PHVS) rose nearly 22% on Wednesday after the company announced positive results from the phase III RAPIDe-3 study evaluating its lead pipeline drug deucri ...